Moderna Announces New England Journal of Medicine Publication of Pivotal Phase 3 Clinical Safety and Efficacy Data for Its Investigational Seasonal Influenza Vaccine, mRNA-1010

🌐 Yahoo Finance —
Moderna Announces New England Journal of Medicine Publication of Pivotal Phase 3 Clinical Safety and Efficacy Data for Its Investigational Seasonal Influenza Vaccine, mRNA-1010

AI Summary

Moderna has announced the publication of crucial clinical data regarding its investigational seasonal influenza vaccine, mRNA-1010, in a prominent medical journal. This data is pivotal for assessing the vaccine's safety and efficacy.

Markets Health Moderna influenza vaccine clinical data mRNA-1010 medical publication

Read original source →